New cancer drug ADCX-020 enters first human trials for advanced tumors

NCT ID NCT07238075

First seen Nov 20, 2025 · Last updated May 15, 2026 · Updated 18 times

Summary

This early-phase study tests a new cancer drug, ADCX-020, in about 290 adults with advanced solid tumors that have stopped responding to standard treatments. The drug is an antibody-drug conjugate designed to target and kill cancer cells. The study first finds a safe dose, then tests that dose in different cancer types to see if it shrinks tumors.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC SOLID TUMORS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Blacktown Hospital

    NOT_YET_RECRUITING

    Sydney, New South Wales, 2148, Australia

  • Cancer Research SA

    NOT_YET_RECRUITING

    Adelaide, South Australia, 5000, Australia

  • Macquarie University

    NOT_YET_RECRUITING

    Sydney, New South Wales, 2109, Australia

  • Sunshine Coast University Private Hospital

    RECRUITING

    Birtinya, Queensland, 4575, Australia

Conditions

Explore the condition pages connected to this study.